Kinetic Analysis of Dominant Intraprostatic Lesion of Prostate Cancer Using Quantitative Dynamic [18F]DCFPyL-PET: Comparison to [18F]fluorocholine-PET

Dae-Myoung Yang
University of Western Ontario

Fiona Li
University of Western Ontario

Glenn Bauman
London Health Sciences Centre

Joseph Chin
London Health Sciences Centre

Stephen Pautler
London Health Sciences Centre

Madeleine Moussa
London Health Sciences Centre

Irina Rachinsky
London Health Sciences Centre

John Valliant
Centre for Probe Development and Commercialization

Ting-Yim Lee

Original research

Keywords: Prostate Cancer, [18F]fluorocholine, [18F]DCFPyL, Prostate-specific Membrane Antigen (PSMA), Dynamic Positron Emission Tomography (PET), Kinetic Analysis

---

Abstract

Purpose

Identification of the dominant intraprostatic lesion(s) (DILs) can faciltiate diagnosis and treatment by targeting biologically significant intra-prostatic foci. [18F]DCFPyL is better than [18F]FCH in detecting and localizing DIL because of higher tumour contrast. However, the optimal imaging time for [18F]DCFPyL is in hours. The goal of this study was to investigate whether the different imaging performance of [18F]FCH and [18F]DCFPyL can be explained by their kinetic behaviour in PCa and to evaluate whether DIL can be accurately detected and localized using a short duration dynamic PET.

Methods

19 and 23 PCa patients were evaluated with dynamic [18F]DCFPyL and [18F]FCH PET, respectively. The dynamic imaging protocol with each tracer had a total imaging time of 22 min and consisted of multiple frames with acquisition times from 10−180 s. Tumour and benign tissue regions identified by sextant biopsy were compared using standardized uptake value (SUV) and tracer kinetic parameters from kinetic analysis of time-activity curves.

Results

For [18F]DCFPyL, logistic regression identified K_i and k_4 as the optimal model to discriminate tumour from benign tissue (84.2% sensitivity and 94.7% specificity) while only SUV was predictive for [18F]FCH (82.6% sensitivity and 87.0% specificity) The higher k_3 (binding) of [18F]FCH than [18F]DCFPyL explains why [18F]FCH SUV can differentiate tumour from benign tissue within minutes of injection. Superior [18F]DCFPyL tumour contrast was due to the higher k_4/k_3 (more rapid washout) in benign tissue compared to tumour tissue.

Conclusions

DIL was detected with good sensitivity and specificity using 22-min dynamic [18F]DCFPyL PET and avoids the need for delayed imaging timepoints. The dissimilar in-vivo kinetic behaviour of [18F]DCFPyL and [18F]FCH could explain their different SUV images.

Trial Registration:

ClinicalTrials.gov, NCT04009174. Registered July 5, 2019 − retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04009174?term=NCT04009174&draw=2&rank=1

Introduction

Prostate cancer (PCa) is the most frequent cancer and one of the most common causes of cancer death in men in the United States and Canada [1,2]. Positron emission tomography (PET) targeting prostate-specific membrane antigen (PSMA), a type II integral membrane protein, is generating significant interest recently. PSMA is a highly promising target for localizing and detecting PCa because it is overexpressed 100- to 1000-fold in malignant compared to benign prostate tissue [3]. Prior to PSMA, choline-based tracers that depend on increased phosphorylation of choline in lipid metabolism were widely used [4-6]. In comparison, radiotracers targeting PSMA, such as ^{68}Ga-PSMA-11 and [^{18}F]DCFPyL, afford better image quality and PCa detection rate than choline-based radiotracers [7-9]. Since previous clinical studies had shown that [^{18}F]fluorocholine ([^{18}F]FCH) PET cannot differentiate benign hyperplasia from PCa, it is not recommended for localizing PCa [10-11]. However, PSMA PET requires a longer delayed imaging time than [^{18}F]FCH PET to achieve optimal standardized uptake value (SUV) contrast between PCa and background [12-17]. For example, it has been advocated that [^{18}F]DCFPyL PET imaging requires 1-2 h delayed imaging time compared with 7-30 min for [^{18}F]FCH PET [8-11].

Even though PET SUV with a PSMA ligand, such as [^{18}F]DCFPyL, showed high image quality and can visualize small prostate lesions with excellent sensitivity [18], it is a single time point measurement and is unable to completely describe the uptake of the tracer. The uptake of PET tracer in tissue, as measured by the SUV, is determined by the combined effects of three processes: tracer delivery via blood flow, exchange between vessels and tissue, and binding to and dissociation from the target. A single uptake measurement cannot differentiate among the 3 different processes [19]. Therefore, SUV is dependent on the time after injection when the measurement is made [20]. Moreover, these processes may vary among radiotracers, and they can be different among tumours of the same tumour type because of tumour heterogeneity. Instead, dynamic PET with its multiple time point measurements following injection is suited to dissect the processes involved in the distribution and uptake of radiotracers and it can provide additional metrics related to the target specific molecular/metabolic processes for potential better differentiation of tumour from benign tissue.

The goal of this study was to investigate whether the different behaviour of [^{18}F]DCFPyL and [^{18}F]FCH in PCa can be explained by kinetic analysis and to evaluate which kinetic parameters derived from dynamic [^{18}F]FCH and [^{18}F]DCFPyL PET are more sensitive than SUV to localize and detect dominant intraprostatic lesion (DIL) identified by prostate sextant biopsy report.

Methods

Patients

This prospective clinical study was approved by Institutional Research Ethics Board. All participants in this study provided written informed consent before the study. Enrolled subjects were men with untreated biopsy-proven localized PCa. The inclusion criteria were as follows: aged 18 years or older; biopsy

confirmed PCa; and suitable for and consenting to radical prostatectomy for treatment, or repeat biopsy as the standard of care. 52 PCa patients were recruited into the study. The first 25 enrolled patients had dynamic [18F]FCH PET, while the last 27 patients had dynamic [18F]DCFPyL PET. However, 23 and 19 patients received [18F]FCH and [18F]DCFPyL PET, respectively, because of patients withdrawing from the study or failure of tracer production. Fig. 1 shows the flow chart of the study.

3D-Transrectal Ultrasound (TRUS)-Guided Prostate Sextant Biopsy

All patients had undergone systematic TRUS-guided biopsy (6- or 12- core) before the dynamic PET scan. The prostate sextants with the highest volume and/or highest grade cancer on biopsy were designated as harboring a DIL and this information was extracted from the clinical biopsy report by one of the investigators (GB) and the involved sextants correlated to the SUV image from the dynamic PET scan (see next section).

Dynamic PET Imaging Acquisition

Dynamic [18F]FCH and [18F]DCFPyL PET imaging were performed on a Discovery VCT (GE Healthcare, Waukesha, WI, USA) PET/CT scanner. A CT scan for attenuation correction was taken first with patients lying supine on the patient couch. The dynamic PET scan set to cover the whole prostate and common iliac arteries was started simultaneously as the intravenous injection of 4 MBq/kg (median 381 MBq; range 280-538 MBq) [18F]FCH or 325 MBq (median 335 MBq; 280-348 MBq) [18F]DCFPyL without the patient moving from the CT scan position. The dynamic PET scan was acquired for 22-min under quiet breathing with variable frame lengths of 10 s (10 frames), 20 s (5), 40 s (4), 60 s (4) and 180 s (4). SUV of [18F]FCH or [18F]DCFPyL was measured by averaging the last four dynamic PET images which was equivalent to 12 minutes of acquisition starting at 10 minutes post-injection.

Dynamic PET Imaging Analysis

The dynamic PET images and SUV images were analyzed on an AW Workstation (AW4.7, GE Healthcare). In the DIL region indicated by pre-operative prostate sextant biopsy, regions of interest (ROIs) were drawn in all slices showing the largest lesion by thresholding SUV $\geq$ 50% of maximum SUV (SUV_{max}). The same number of benign tissue ROIs as DIL ROIs were outlined in sextant locales not involved according to prostate sextant biopsy. For kinetic analysis, the arterial time-activity curve (TAC) was obtained from a region inside a common iliac artery. TACs for DIL and benign tissue were obtained by finding the area-weighted average of the mean activity in each DIL and benign ROI for all slices. The dynamic TACs of both tracers were analyzed using the flow modified standard two extravascular tissue compartment model (F2TCM), as described in a previous publication [18]. This model accounts for the combined effects of the three tracer uptake processes: tracer delivery via blood flow; bidirectional permeation of the blood-tissue barrier during tracer transit through vessels; and binding to and dissociation from the target.

Kinetic parameters – K_1 (influx rate constant) in mL/min/g, k_2 (efflux rate constant) in min^{-1}, k_3 (binding rate constant) in min^{-1}, k_4 (dissociation rate constant) in min^{-1}, $K_i = K_1 k_3/(k_2+k_3+k_4)$ (net uptake rate constant from plasma) in mL/min/g, DV = $K_1/k_2(1+k_3/k_4)$ (distribution volume) in mL/g and k_4/k_3 (normalized washout rate constant (inverse of binding potential)) were estimated by deconvolving the arterial TAC from the tissue TAC. A custom developed MATLAB program iteratively adjusted the model parameters until the sum of squared deviations of the fitted TAC, calculated as the convolution of the arterial TAC and the flow scaled impulse residue function of the F2TCM, from the tissue TAC was minimized.

Statistical Analysis

All statistical analyses were performed using SPSS (IBM SPSS Statistics 23, IBM Analytics) for 2-sided testing with significance set at $P<0.05$. For each PET tracer, the F2TCM parameters of DIL and benign prostatic tissue were compared using nonparametric Wilcoxon matched-pair signed-rank test. The kinetic parameters of [18F]FCH and [18F]DCFPyL were compared using the nonparametric Mann-Whitney U test. Logistic regression with backward selection was used to determine the most sensitive set of kinetic parameters to distinguish DIL from benign tissue for each tracer. From that analysis, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and receiver operating characteristic (ROC) curve of the dynamic [18F]FCH and [18F]DCFPyL PET imaging were assessed.

Results

23 patients (median age 62 years, range 49-76 years) and 19 patients (median age 63 years, range 53-69 years) received dynamic PET with [18F]FCH and [18F]DCFPyL, respectively (Fig. 1). The median pre-operative PSA level within 2 week before the day of the imaging session of [18F]FCH PET or [18F]DCFPyL PET was 4.8 ng/mL (range 0.9-15.0 ng/mL) and 5.4 ng/mL (range 3.5-25.5 ng/mL), respectively. The characteristics of the two patient cohorts are listed in Table 1. Fig. 2 shows the measured arterial and tissue TAC from a patient from each cohort, and the fit using the F2TCM. Fig. 3 shows maximum intensity projections of SUV maps of the same patients, as in Fig. 2.

	[^{18}F]FCH (n=23)	[^{18}F]DCFPyL (n=19)	P-value
Age [y]	61.1 ± 6.9 (49-76)*	62.4 ± 4.7 (50-67)*	0.58
Weight [kg]	93.3 ± 14.3 (67-122)*	86.4 ± 17.1 (30-109)*	0.46
Height [cm]	175.7 ± 5.0 (168-185)*	177.1 ± 6.3 (165-191)*	0.37
PSA [ng/mL]	5.9 ± 3.4 (0.9-15.0)*	8.4 ± 5.8 (3.5-25.5)*	0.42
Histology − n(%)			1.00
Adenocarcinoma	23 (100)	19 (100)	
pT Stage − n(%)			0.93
T2a	1 (4.3)	0 (0)	
T2c	12 (52.2)	11 (57.9)	
T3a	5 (21.7)	7 (36.8)	
T3b	5 (21.7)	1 (5.3)	
pN Stage − n(%)			0.79
N0	19 (82.6)	19 (100)	
N1	1 (4.3)	0 (0)	
NX	3 (13.0)	0 (0)	
Gleason score − n(%)			0.94
6 (3+3)	2 (8.7)	1 (5.3)	
7 (3+4)	17 (69.6)	16 (84.2)	
7 (4+3)	4 (17.4)	2 (10.5)	
9 (5+4)	1 (4.3)	0 (0)	
Proportion of Prostate Involved by Tumour (%)	14.3 ± 15.5 (1-80)*	13.7 ± 7.7 (5-30)*	0.49

Note. Data are number of patients, with the percentage in parentheses unless otherwise indicated.
* Data are means ± standard deviation, with the range in parentheses.

Comparison of Kinetic Parameters between DIL and Benign Tissue Parameters

Kinetic parameters of DIL were compared with those of benign tissue in Fig. 4. For [18F]FCH cohort, significant differences in median value of K_1 (0.27 vs. 0.23 mL/min/g; P<0.001), SUV (3.88 vs. 2.75 g/mL; P<0.001) and DV (6.07 vs. 4.31 mL/g; P=0.04) were found. The median values of the same three parameters and also k_4/k_3 were different between DIL and benign tissue for [18F]DCFPyL cohort - K_1 (0.30 vs. 0.24 mL/min/g; P=0.02), SUV (2.76 vs. 1.96 g/mL; P<0.001), DV (3.89 vs. 1.42 mL/g; P=0.01) and k_4/k_3 (0.41 vs. 0.69 unitless; P=0.03).

Diagnostic Performance for Detecting and Localizing DIL using PET Kinetic Parameters

For the [18F]FCH group (n=23), using logistic regression with backward elimination of all parameters having a univariable logical regression P<0.2, the most sensitive model of PET parameters for identifying DIL from benign tissue consisted of SUV alone (P<0.001) - sensitivity 82.6%, specificity 87.0%, PPV 86.4%, NPV 83.3%, and area under the ROC curve (AUC) 0.88. For [18F]DCFPyL, logistic regression with backward elimination of all parameters having a univariable logical regression P<0.2 yielded the combination of K_i and k_4 as the most sensitive model (P<0.001) that distinguished tumour to benign tissue - sensitivity 84.2%, specificity 94.7%, PPV 94.1%, NPV 85.7%, and AUC 0.93. A representative case of [18F]DCFPyL SUV, K_i and k_4 parametric maps is shown in Fig. 5.

Kinetic Parameters of [18F]FCH vs [18F]DCFPyL

The in-vivo behaviour of [18F]FCH in 23 patients and [18F]DCFPyL in 19 patients were compared using kinetic parameters estimated from dynamic PET (see Fig. 4). There were no significant differences in K_1 and k_2 between the two tracers in both tumour and benign tissue. For [18F]FCH vs [18F]DCFPyL (mean ± SD) in tumour tissue, there was significant difference in SUV (3.98 ± 1.08 vs. 4.12 ± 3.64 ; P=0.01), k_3 (2.91 ± 2.03 vs. 0.44 ± 1.04 min^{-1}; P=0.001), k_4 (2.16 ± 2.13 vs. 0.08 ± 0.07 min^{-1}; P<0.001), K_i (0.20 ± 0.14 vs. 0.10 ± 0.10 mL/min/g; P=0.002) and DV (4.50 ± 3.83 vs. 3.40 ± 2.26 mL/g; P=0.03). In benign tissue, there was significant difference in SUV (2.66 ± 0.81 vs. 1.92 ± 0.37 g/mL; P=0.001), k_3 (2.63 ± 2.06 vs. 0.51 ± 1.16 min^{-1}; P<0.001), k_4 (1.75 ± 2.03 vs. 0.13 ± 0.12 min^{-1}; P=0.004), K_i (0.14 ± 0.07 vs. 0.05 ± 0.04 mL/min/g; P<0.001) and DV (3.01 ± 2.12 vs. 1.50 ± 0.55 mL/g; P=0.001). Fig. 6 shows the normalized washout rate constant (k_4/k_3) of [18F]FCH and [18F]DCFPyL in DIL and benign tissue. This washout constant or inverse of binding potential was 1.86-fold higher in benign tissue than tumour for [18F]DCFPyL (P<0.05); however, for [18F]FCH, it was similar for both tissue types. In addition, for benign tissue, the normalized washout constant was higher for [18F]DCFPyL.

Discussion

In this study, we estimated the F2TCM parameters of [^{18}F]FCH and [^{18}F]DCFPyL from dynamic PET studies of PCa patients and investigated whether these kinetic parameters can differentiate DIL from benign tissue and explain the different SUV image characteristics observed with the two tracers.

Logistic regression with backward elimination of variables showed that the combination of K_i and k_4 and SUV alone were sensitive models for localizing and differentiating tumour from benign prostatic tissue with [^{18}F]DCFPyL and [^{18}F]FCH, respectively. The former tracer was more accurate according to AUC (0.93 vs 0.88; P<0.001 for both). Previous experience with [^{18}F]FCH illustrated that it is challenging to localize the DIL without the prostate biopsy report because the tracer is not highly specific to PCa [10,11,21,22]. However, in selected patients who have undergone multiple TRUS-guided biopsies with negative findings, [^{18}F]FCH SUV map could be helpful and contribute valuable additional information for detection of the primary tumour [11].

For [^{18}F]DCFPyL, K_i and k_4 were more sensitive than the semi-quantitative SUV used routinely in the clinic. Previous studies had demonstrated that optimal image qualities (SUV tumour to background ratio) was achievable at 60-120 mins post-injection [16,17] due to reduction in nonspecific background [23,24]. However, in this study, a 22-min dynamic PET acquisition with kinetic analysis to derive K_i and k_4 of the F2TCM was able to differentiate tumour from benign tissue. Therefore, use of dynamic [^{18}F]DCFPyL imaging may improve the efficiency of DIL imaging with PET by eliminating the 1-2 hr wait time between injection and SUV imaging.

The observed better contrast between DIL and benign tissue with [^{18}F]DCFPyL than [^{18}F]FCH and that this contrast has been reported to increase with time[16,17] could be explained by the different kinetic behavior of the two tracers. Median k_3, k_4, K_i and SUV values of [^{18}F]DCFPyL were smaller than those of [^{18}F]FCH for both tumour and benign tissue. These differences in kinetics could explain why with [^{18}F]FCH imaging can start soon after the tracer injection because [^{18}F]FCH bound and dissociated more quickly than [^{18}F]DCFPyL [10,12-14,25]. Higher normalized washout rate constant (k_4/k_3) indicates rapid washout relative to binding in the tissue. Fig. 6 shows that for [^{18}F]DCFPyL, normalized washout rate constant was significantly higher in benign tissue than tumour (P<0.05) while for [^{18}F]FCH, this rate constant was not significant different. Therefore, the contrast between tumour (DIL) and benign tissue would increase over time with [^{18}F]DCFPyL while the same contrast would not change over time with [^{18}F]FCH. Taken together, the kinetic analysis suggests that with [^{18}F]FCH, SUV imaging can be done soon after injection but contrast between tumour and benign tissue does not improved over time. In contrast, with [^{18}F]DCFPyL, to optimize contrast between tumour and benign tissue, SUV imaging has to be delayed, as literature suggested, to 1-2 hr post injection. However, with kinetic analysis of dynamic [^{18}F]DCFPyL, the imaging time can be shortened to 22-min post injection and the combination of K_i and k_4 could identify DIL with high accuracy (AUC = 0.93).

There are limitations with our study. First, dynamic [^{18}F]DCFPyL imaging was limited to 22-minute which precluded comparison with SUV at 1-2 h post injection for separating tumour (DIL) from benign tissue. Second, burden of disease on sextant biopsy was used for defining DIL locations and this may be subject to sampling error. Third, ideally the performance of [^{18}F]FCH and [^{18}F]DCFPyL would be compared in the same patient group but availability of the tracer (and concerns about cumulative radiation dose) precluded such a comparison. The two patient cohorts were accrued sequentially on the same research protocol (same eligibility) and both cohorts had similar clinical characteristics (Table 1) reducing possible bias. [24,26].

Conclusions

Patients with PCa were studied with dynamic [^{18}F]FCH PET and dynamic [^{18}F]DCFPyL PET over a short acquisition time of 22-min. Multiple kinetic parameters were derived with the custom developed F2TCM from the dynamic studies and compared for distinguishing tumour from benign tissue. Among all the [^{18}F]FCH PET and [^{18}F]DCFPyL parameters investigated, the logistic regression model based on K_i (net uptake rate constant from plasma) and k_4 (dissociation rate constant from binding) of [^{18}F]DCFPyL was the most accurate in identifying DIL containing sextants on prostate biopsy and these findings support the incorporation of dynamic imaging sequences into PET/CT protocols using [^{18}F]DCFPyL.

Compliance with Ethical Standards

Funding:

This study was funded by the Ontario Institute for Cancer Research, the Canadian Institute for Health Research and the Canada Foundation for Innovation (Leading Edge Fund grant #11358).

Conflict of Interest:

All authors declare that they have no conflict of interest.

Ethical approval:

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (University of Western Ontario Research Ethics Boards) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent:

Informed consent was obtained from all individual participants included in the study.

Abbreviations

FCH = Flourocholine

DCFPyL = 2-(3-{1-carboxy-5-[(6-[^{18}F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid

PSA = Prostate specific antigen

Declarations

Funding:

The project was supported by the Ontario Institute for Cancer Research, the Canadian Institute for Health Research and a Leading Edge Fund grant (#11358) from the Canada Foundation for Innovation.

Acknowledgements:

None

Competing Interest:

No author has conflict of interest to declare.

Authors' contributions:

Conceptualization: Glenn Bauman, Joseph Chin, Stephen Pautler, Madeleine Moussa, Irina Rachinsky, Ting-Yim Lee

Design: Dae-Myoung Yang, Glenn Bauman, Joseph Chin, Stephen Pautler, Madeleine Moussa, Irina Rachinsky, John Valliant, Ting-Yim Lee

Data Collection: Dae-Myoung Yang, Glenn Bauman, Joseph Chin, Stephen Pautler, Madeleine Moussa, Irina Rachinsky, Ting-Yim Lee

Data Analysis: Dae-Myoung Yang, Fiona Li, Glenn Bauman, Ting-Yim Lee

Discussion: Dae-Myoung Yang, Glenn Bauman, Ting-Yim Lee

Final Proofing: Dae-Myoung Yang, Fiona Li, Glenn Bauman, Joseph Chin, Stephen Pautler, Madeleine Moussa, Irina Rachinsky, John Valliant, Ting-Yim Lee

Ethics approval and consent to participate:

Ethics approval of all patient study procedures were granted by Institution's Research Ethics Board. All participating patients provided informed consent.

Consent for publication:

Not applicable

Availability of data and material:

Data and material presented are available after publication of this manuscript. Interested parties can contact the corresponding author ⬚ tlee@robarts.ca

Reference

[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. *CA Cancer J Clin*. 2018; https://doi.org/10.3322/caac.21442.

[2] Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society. 2019. https://cancer.ca/Canadian-Cancer-Statistics-2019-EN. Accessed 25 May 2020.

[3] Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA−PET in prostate cancer management. *Nat Rev Urol*. 2016; https://doi.org/10.1038/nrurol.2016.26.

[4] De Jong IJ, Pruim J, Elsinga PH, et al. Visualization of prostate cancer with ^{11}C-choline positron emission tomography. *Eru Urol*. 2002;42(1):18-23.

[5] Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. The *J Nucl Med*. 1998;39(6):990.

[6] Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. *Eur J Nucl Med*. 2000;27(9):1415-9.

[7] Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a ^{68}Ga-labelled PSMA ligand and ^{18}F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging*. 2014; https://doi.org/10.1007/s00259-013-2525-5.

[8] Schwenck J, Rempp H, Reischl G, et al. Comparison of ^{68}Ga-labelled PSMA-11 and ^{11}C-choline in the detection of prostate cancer metastases by PET/CT. *Eur J Nucl Med Mol Imaging*. 2017; https://doi.org/10.1007/s00259-016-3490-6.

[9] Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [^{18}F]DCFPyL and [^{68}Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. *Mol Imaging and Biol*. 2015; https://doi.org/10.1007/s11307-015-0866-0.

[10] Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. *Radiology*. 2005; https://doi.org/10.1148/radiol.2352040494.

[11] Igerc I, Kohlfürst S, Gallowitsch HJ, et al. The value of ^{18}F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. *Eur J Nucl Med Mol Imaging*. 2008; https://doi.org/10.1007/s00259-007-0686-9.

[12] Häcker A, Jeschke S, Leeb K, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [^{18}F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. The *J Urol*. 2006; https://doi.org/10.1016/j.juro.2006.07.037.

[13] Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?. *Mol Imaging Biol*. 2006; https://doi.org/10.1007/s11307-005-0023-2.

[14] Jadvar H. Prostate cancer: PET with ^{18}F-FDG, ^{18}F-or ^{11}C-acetate, and ^{18}F-or ^{11}C-choline. *J Nucl Med*. 2011; https://doi.org/10.2967/jnumed.110.077941.

[15] Afshar-Oromieh A, Sattler LP, Mier W, et al. The clinical impact of additional late PET/CT imaging with ^{68}Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. *J Nucl Med*. 2017; https://doi.org/10.2967/jnumed.116.183483.

[16] Rowe SP, Macura KJ, Mena E, et al. PSMA-based [^{18}F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. *Mol Imaging Biol*. 2016; https://doi.org/10.1007/s11307-016-0957-6.

[17] Wondergem M, van der Zant FM, Knol RJ, et al. ^{18}F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. *J Nucl Med*. 2017; https://doi.org/10.2967/jnumed.117.192658.

[18] Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[^{18}F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [^{18}F] DCFPyL, a PSMA-based PET imaging agent for prostate cancer. *Clin Cancer Res*. 2011; https://doi.org/10.1158/1078-0432.CCR-11-1357.

[19] Yang DM, Palma D, Louie A, et al. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid ^{18}F-fluorodeoxyglucose-positron emission tomography and CT perfusion study. *J Med Imaging Radiat Onco*. 2019; https://doi.org/10.1111/1754-9485.12807.

[20] Keyes Jr JW. SUV: standard uptake or silly useless value?. *J Nucl Med*. 1995;36(10):1836-9.

[21] Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, Souvatzogluou M, Gildehaus FJ, Wester HJ, Dresel S. Value of 11 C-choline PET and PET/CT in patients with suspected prostate cancer. *Eur J Nucl Med Mol Imaging*. 2007; https://doi.org/10.1007/s00259-006-0190-7.

[22] Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. *Theranostics*. 2012; https://doi.org/10.7150/thno.4008.

[23] Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R. Comparison of [18F] DCFPyL and [68Ga] Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. *Mol Imaging Biol*. 2015; https://doi.org/10.1007/s11307-015-0866-0.

[24] Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC. Initial evaluation of [18F] DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. *Mol Imaging Biol*. 2015; https://doi.org/10.1007/s11307-015-0850-8.

[25] Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, de Jong IJ. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. *Eur J Nucl Med Mol Imaging*. 2005; https://doi.org/10.1007/s00259-004-1741-4.

[26] Quak E, Blanchard D, Houdu B, et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. *Eur J Nucl Med Mol Imaging*. 2018; https://doi.org/10.1007/s00259-017-3911-1.

Figures

Figure 1

Study flowchart showing patient enrollment. Abbreviations: FCH = Flourocholine; DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid.

Figure 2

An iliac artery TAC (gray), the tumour TAC (light gray line with open circle marker, scaled up 4x to improve visibility) and the benign tissue TAC (light gray line with x marker, scaled up 4x) of a [18F]FCH patient (a) and a [18F]DCFPyL patient (b). Both patients had similar prostate cancer characteristics (PSA level 10.3 vs. 12.94 ng/mL; Gleason score 7 (3+4), the proportion of prostate involved with tumour 10%). The fitted curves (black) for both tracers using the F2TCM showed a strong correlation with measured TACs (R2 > 0.93). Abbreviations: TAC: Time-activity curve; FCH = Flourocholine; DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; PSA = Prostate specific antigen; F2TCM = Flow modified standard two extravascular tissue compartment model.

Figure 3

PET/CT Images of the same patients as Fig. 2 showing maximum intensity projection of [18F]FCH PET SUV map in an axial view superimposed on CT (a) and in a coronal view by itself (b); the same two views for a [18F]DCFPyL study on another patient are shown in (c) and (d). The colour bar shows the scale of SUV. Localization of DIL (yellow arrow) with PET in both patients agreed with pre-operative prostate sextant biopsy. [18F]DCFPyL SUV map shows superior tumour contrast relative to benign prostatic tissue and better localization of DIL than [18F]FCH. Abbreviations: PET = Positron emission tomography; CT = Computed tomography; FCH = Flourocholine; SUV = Standardized uptake value; DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; DIL = Dominant intraprostatic lesion.

Figure 4

Comparison of [18F]FCH and [18F]DCFPyL F2TCM model parameters in DIL and benign tissue. Significant difference (P<0.05) is marked with *. Abbreviations: FCH = Flourocholine; DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; F2TCM = Flow modified standard two extravascular tissue compartment model; DIL = Dominant intraprostatic lesion; K1 = Influx rate; k2 = Efflux rate constant; k3 = Binding rate constant; k4 = Dissociation rate constant; Ki = Net uptake rate constant from plasma; DV = Distribution volume; SUV = standardized uptake value.

Figure 5

Axial CT image (a), axial [18F]DCFPyL SUV map (range: 0 – 10.0 g/mL) superimposed on CT (b), coronal [18F]DCFPyL PET (range: 0 – 10.0 g/mL) (c), Ki parametric map (d), k4 parametric map (e) and localized tumour in red using the classifier from logistic regression (f), in a 64-year-old man with PCa (Gleason score 7 (3+4)). Pre-op PSA was 8.17 ng/mL. Mean SUV of the tumour ROI was 13.4 g/mL. Abbreviations: CT = Computed tomography; DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; SUV = standardized uptake value; PET = Positron emission tomography; Ki = Net uptake rate constant from plasma; k4 = Dissociation rate constant; PCa = Prostate cancer; PSA = Prostate specific antigen; ROI = Region of interest.

Figure 6

Comparison of normalized washout rate constant (k4/k3) (mean ⬛ SEM) of [18F]FCH and [18F]DCFPyL in both tumour and benign tissues, significant differences are marked with (*), P<0.05. Abbreviations: k4/k3 = Normalized washout rate constant (inverse of binding potential); SEM = standard error of the mean; FCH = Flourocholine; DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid.